Physician profile
Navin Gupta
NPI 1457344673
$13,576.13
in general payments reported to CMS, 2019-2025
33 companies · $4,758 in 2025
The $4,758 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,702 · 2020: $264 · 2021: $439 · 2022: $1,078 · 2023: $785 · 2024: $4,550 · 2025: $4,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,677 · Food and Beverage: $4,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,677.16 |
| Food and Beverage | $4,415.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,848.44 | 2021-2025 | Aveir, Perclose Proglide, Accent |
| Medtronic, INC. | $2,184.10 | 2021-2025 | Micra, Linq II, Resolute Onyx |
| Medtronic Vascular, INC. | $642.04 | 2019-2020 | |
| Abiomed | $572.19 | 2019-2025 | Impella |
| Boston Scientific Corporation | $482.63 | 2019-2025 | Wolverine Coronary Cutting Balloon |
| Actelion Pharmaceuticals US, INC. | $401.31 | 2022-2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $370.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $241.08 | 2022-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $230.48 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $217.64 | 2019-2024 | Xarelto |
| Pfizer INC. | $176.14 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.95 | 2019-2023 | Jardiance |
| Amgen INC. | $117.02 | 2019-2025 | Repatha, Repatha |
| Asahi Intecc USA, INC. | $116.24 | 2020 | |
| Inari Medical, INC. | $99.22 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $98.90 | 2020-2021 | |
| Cardiovascular Systems INC. | $90.43 | 2019-2020 | |
| Shockwave Medical, INC | $77.09 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $69.78 | 2022-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.36 | 2021-2025 | Lifevest |
| Teleflex LLC | $43.70 | 2019 | |
| Penumbra, INC. | $41.72 | 2019 | |
| Lantheus Medical Imaging, INC. | $36.05 | 2024-2025 | |
| Kestra Medical Technology Services, INC. | $34.19 | 2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $28.32 | 2021 | |
| Daiichi Sankyo INC. | $23.76 | 2024 | Injectafer |
| Philips North America LLC | $20.65 | 2019 | |
| Elutia, INC. | $15.47 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $14.48 | 2024 | Arcalyst |
| Molnlycke Health Care US, LLC | $13.93 | 2020 | |
| Terumo Medical Corporation | $13.03 | 2019 | |
| Novo Nordisk INC | $12.78 | 2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.